[{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Limertinib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Aosaikang Pharmaceutical \/ Innovent Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Aosaikang Pharmaceutical \/ Innovent Biologics"}]

Find Clinical Drug Pipeline Developments & Deals by Aosaikang Pharmaceutical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the agreement, Innovent will obtain the exclusive commercialization rights for limertinib, a third-generation EGFR inhibitor for the treatment of lung cancer, in mainland China.

                          Brand Name : ASK120067

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 07, 2024

                          Lead Product(s) : Limertinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Innovent Biologics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank